Sy Mukherjee
Fortune
New York, NY, United States
Contact Sy
Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.
| Recent: |
|
Recent articles by Sy:
Getting back to the office in the midst of coronavirus is going to be complicated
Reopening workplaces will be a lengthy process dependent on the accuracy of antibody tests, tracking and tracing measures, and other nuances. → Read More
Moderna’s coronavirus vaccine expectations game
It will take a lot more data before we figure out whether Moderna's COVID-19 vaccine really works. → Read More
Coronavirus health care winners, losers: Hospitals, doctors, insurance companies, pharma companies
Hospitals, insurers, and drug makers all have different roles—and different stakes—in the business of coronavirus and COVID-19. → Read More
Coronavirus vaccine: What you should know about Moderna's promising, early-stage data
Moderna's coronavirus vaccine to ward off COVID-19 produced antibodies in clinical trial participants, a sign it may help protect against the virus. → Read More
Antibody testing’s chicken and egg problem
Antibody testing will be critical to reopening the economy and saving lives. It's also a series of contradictions. → Read More
New coronavirus stimulus: Takeaways from the House Democrats' new $3 trillion stimulus bill
The bill rests on three pillars: Reopening the economy safely, honoring heroes, and putting “much-needed” money into the pockets of Americans. → Read More
Antibody testing will be key—once we understand what the results mean
It will take time to parse the information on which antibody tests give accurate results—and what those results actually mean for reopening our cities. → Read More
Articles by Sy Mukherjee
© 2019 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy (Your California Privacy Rights) | CCPA Do Not Sell My Information FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may… → Read More
Gilead’s moral (and financial) COVID-19 conundrum
How will Gilead balance its duties to shareholders and the public? → Read More
Coronavirus treatment: Remdesivir is the first FDA-approved coronavirus treatment. So why is Gilead's stock plunging?
Gilead, which has the first FDA-authorized coronavirus treatment, has seen its stock slump. → Read More
The communities we forget during COVID-19
Communities ranging from people of color to those with rare diseases are suffering the most during the coronavirus crisis. → Read More
Gilead's remdesivir won't be a COVID-19 miracle cure, but it's still an important first step
Gilead's coronavirus drug remdesivir is expected to be quickly approved by the FDA. → Read More
The coronavirus pandemic is impacting critical research into neuromuscular diseases
Those with neuromuscular diseases are high risk for COVID-19, which makes leaving the house even harder than it was before. → Read More
The 3-pronged approach to defeating the coronavirus
Testing, treatments, and vaccines are required to tackle coronavirus—but it's complicated. → Read More
Elective surgeries—mostly paused due to the pandemic—are critical to hospital finances
Hospitals are in a precarious position as they're overwhelmed with coronavirus patients and been forced to put their biggest money makers on the back burner. → Read More
Coronavirus vaccines, treatment, and diagnosis: How Big Pharma can come to the world's rescue
The pandemic may finally do for the pharmaceutical industry what relentless TV advertising cannot: show off its power to innovate. → Read More
Coronavirus tests and their discontents
Look out for coronavirus tests which may not work. → Read More
Coronavirus tests in the U.S.: How these forms of COVID-19 testing differ
There are key scientific—and practical—differences among these various diagnostics. → Read More
The key problem to solve in the quest for coronavirus treatments
We still don't know exactly how COVID-19 kills its victims. → Read More
Articles by Sy Mukherjee
© 2019 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy (Your California Privacy Rights) | CCPA Do Not Sell My Information FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may… → Read More